On the other hand, miR-101 was reported to inhibit tumor aggressiveness through targeting EZH2 which is an epigenetic regulator of cell survival, proliferation, CSC phenotype and function, in various cancers including endometrial cancer [21] prostate cancer [22], pancreatic cancer [23]. This evidence concerns the gene EZH2 and prostate cancer.